EC grants orphan medicinal product status to Rocket's RP-A601 [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
PKP2-ACM is an inherited heart disease that poses a significant risk of arrhythmias, cardiac abnormalities and sudden cardiac death. The decision follows a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). RP-A601 is a recombinant adeno-associated serotype rh74 (AAVrh74) capsid containing a functional version of the human PKP2 transgene. It is administered as a single intravenous infusion and is currently under investigation as a one-time, potentially curative treatment. The therapy aims to improve survival and quality of life for patients with PKP2-ACM, a condition for which there are no curative treatments available. An orphan medicinal product designation is awarded to new therapies for rare, life-threatening or chronically debilitating conditions. In the European Union, this applies to diseases affecting fewer than five in 10,000 persons. Benefits of the designation include protocol assistance from the EMA, acc
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Needham & Company LLC from $53.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)Business Wire
- Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
RCKT
Earnings
- 5/6/24 - Beat
RCKT
Sec Filings
- 6/28/24 - Form 8-K
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- RCKT's page on the SEC website